In 2006, the pivotal role of CD44 in the interaction between LSCs and their niche was elucidated, demonstrating that engraftment of human AML cells in immunodeficient mice was decreased after treatment with an activating antibody to CD44 [24]. This evidence concerns the gene CD44 and acute myeloid leukemia.